These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 22606323)

  • 1. Direct and allosteric inhibition of the FGF2/HSPGs/FGFR1 ternary complex formation by an antiangiogenic, thrombospondin-1-mimic small molecule.
    Pagano K; Torella R; Foglieni C; Bugatti A; Tomaselli S; Zetta L; Presta M; Rusnati M; Taraboletti G; Colombo G; Ragona L
    PLoS One; 2012; 7(5):e36990. PubMed ID: 22606323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly.
    Ibrahimi OA; Zhang F; Hrstka SC; Mohammadi M; Linhardt RJ
    Biochemistry; 2004 Apr; 43(16):4724-30. PubMed ID: 15096041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists.
    Presta M; Oreste P; Zoppetti G; Belleri M; Tanghetti E; Leali D; Urbinati C; Bugatti A; Ronca R; Nicoli S; Moroni E; Stabile H; Camozzi M; Hernandez GA; Mitola S; Dell'Era P; Rusnati M; Ribatti D
    Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):71-6. PubMed ID: 15514208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural insights into the interaction of human S100B and basic fibroblast growth factor (FGF2): Effects on FGFR1 receptor signaling.
    Gupta AA; Chou RH; Li H; Yang LW; Yu C
    Biochim Biophys Acta; 2013 Dec; 1834(12):2606-19. PubMed ID: 24063890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors.
    Foglieni C; Pagano K; Lessi M; Bugatti A; Moroni E; Pinessi D; Resovi A; Ribatti D; Bertini S; Ragona L; Bellina F; Rusnati M; Colombo G; Taraboletti G
    Sci Rep; 2016 Mar; 6():23432. PubMed ID: 27000667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives.
    Leali D; Belleri M; Urbinati C; Coltrini D; Oreste P; Zoppetti G; Ribatti D; Rusnati M; Presta M
    J Biol Chem; 2001 Oct; 276(41):37900-8. PubMed ID: 11473122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors.
    Casu B; Guerrini M; Naggi A; Perez M; Torri G; Ribatti D; Carminati P; Giannini G; Penco S; Pisano C; Belleri M; Rusnati M; Presta M
    Biochemistry; 2002 Aug; 41(33):10519-28. PubMed ID: 12173939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor-2 antagonist and antiangiogenic activity of long-pentraxin 3-derived synthetic peptides.
    Leali D; Alessi P; Coltrini D; Rusnati M; Zetta L; Presta M
    Curr Pharm Des; 2009; 15(30):3577-89. PubMed ID: 19860702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Undersulfated and glycol-split heparins endowed with antiangiogenic activity.
    Casu B; Guerrini M; Guglieri S; Naggi A; Perez M; Torri G; Cassinelli G; Ribatti D; Carminati P; Giannini G; Penco S; Pisano C; Belleri M; Rusnati M; Presta M
    J Med Chem; 2004 Feb; 47(4):838-48. PubMed ID: 14761186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
    Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
    Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The calcium-binding type III repeats domain of thrombospondin-2 binds to fibroblast growth factor 2 (FGF2).
    Rusnati M; Borsotti P; Moroni E; Foglieni C; Chiodelli P; Carminati L; Pinessi D; Annis DS; Paiardi G; Bugatti A; Gori A; Longhi R; Belotti D; Mosher DF; Colombo G; Taraboletti G
    Angiogenesis; 2019 Feb; 22(1):133-144. PubMed ID: 30168023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Membrane heparan sulfate proteoglycan-supported FGF2-FGFR1 signaling: evidence in support of the "cooperative end structures" model.
    Zhang Z; Coomans C; David G
    J Biol Chem; 2001 Nov; 276(45):41921-9. PubMed ID: 11551944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PO-15 - Antiangiogenic small molecule ligands of FGF2 derived from the endogenous inhibitor thrombospondin-1.
    Pinessi D; Foglieni C; Bugatti A; Moroni E; Resovi A; Ribatti D; Rusnati M; Giavazzi R; Colombo G; Taraboletti G
    Thromb Res; 2016 Apr; 140 Suppl 1():S182. PubMed ID: 27161705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The thymidine phosphorylase inhibitor 5'-O-tritylinosine (KIN59) is an antiangiogenic multitarget fibroblast growth factor-2 antagonist.
    Liekens S; Bronckaers A; Belleri M; Bugatti A; Sienaert R; Ribatti D; Nico B; Gigante A; Casanova E; Opdenakker G; Pérez-Pérez MJ; Balzarini J; Presta M
    Mol Cancer Ther; 2012 Apr; 11(4):817-29. PubMed ID: 22302099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived anti-angiogenic pentapeptide.
    Leali D; Bianchi R; Bugatti A; Nicoli S; Mitola S; Ragona L; Tomaselli S; Gallo G; Catello S; Rivieccio V; Zetta L; Presta M
    J Cell Mol Med; 2010 Aug; 14(8):2109-21. PubMed ID: 19627396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the heparin-binding domain of fibroblast growth factor receptor 1 as a potential cancer therapy.
    Ling L; Tan SK; Goh TH; Cheung E; Nurcombe V; van Wijnen AJ; Cool SM
    Mol Cancer; 2015 Jul; 14():136. PubMed ID: 26201468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity.
    Rusnati M; Bugatti A; Mitola S; Leali D; Bergese P; Depero LE; Presta M
    Sensors (Basel); 2009; 9(8):6471-503. PubMed ID: 22454596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Basis of the Antiangiogenic Action of Rosmarinic Acid, a Natural Compound Targeting Fibroblast Growth Factor-2/FGFR Interactions.
    Pagano K; Carminati L; Tomaselli S; Molinari H; Taraboletti G; Ragona L
    Chembiochem; 2021 Jan; 22(1):160-169. PubMed ID: 32975328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain.
    Margosio B; Rusnati M; Bonezzi K; Cordes BL; Annis DS; Urbinati C; Giavazzi R; Presta M; Ribatti D; Mosher DF; Taraboletti G
    Int J Biochem Cell Biol; 2008; 40(4):700-9. PubMed ID: 17996481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 signaling in brain endothelial cells. Specific role for glypican-1 in glioma angiogenesis.
    Qiao D; Meyer K; Mundhenke C; Drew SA; Friedl A
    J Biol Chem; 2003 May; 278(18):16045-53. PubMed ID: 12591930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.